Advertisement

Interplay between anti-inflammatory drugs and eicosanoids in gastrointestinal damage

  • K. D. Rainsford
Part of the Advances in Eicosanoid Research book series (AEIR, volume 2)

Abstract

Inhibition of the synthesis and production of prostaglandins (chiefly E2 and I2) has been considered a major factor in the development of gastrointestinal damage for some years now. Based on the original suggestion by Vane1 in 1971 that ‘aspirin-like’ drugs exert their effects by inhibiting the biosynthesis of prostaglandins (PGs), it was proposed by Main and Whittle2 and others that this property might underly the gastric mucosal damage caused by nonsteroidal anti-inflammatory drugs (NSAIDs). Just before these suggestions were propounded, several workers became interested in the effects on acid-secretion3, anti-ulcer3 and smooth muscle contractile4,5 actions of exogenous prostaglandins on the gastrointestinal (GI) tract and later on the involvement of PGs in the production of diarrhoea by cholera toxin6. Since these and other earlier studies, there has been an enormous upsurge in interest in the fundamental actions of PGs and other eicosanoids on the GI tract and the actions of NSAIDs and steroids on their generation and actions. It is the purpose of this review to focus on (a) the actions of anti-inflammatory drugs on eicosanoid metabolism, and (b) the possible relationship of these effects to the pathogenesis of mucosal damage in different regions of the GI tract. The pharmacological and physiological actions of the various eicosanoids, and their production in the GI tract, are discussed elsewhere in this book and in recent reviews7–14. Here, these aspects will only be considered as they relate to understanding the fundamental role of perturbing eicosanoid metabolism in the development of GI mucosal damage.

Keywords

Gastric Mucosa Mucosal Injury Gastric Mucosal Injury Gastric Injury Gastric Mucosal Damage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vane J.R. (1971). Inhibition of prostaglandin biosynthesis as a mechanism of action of aspirin-like drugs. Nature (London) New Biol., 231, 232–235Google Scholar
  2. 2.
    Main, I.H.M. and Whittle, B.J.R. (1974). Prostaglandins and prostaglandin synthetase inhibitors in gastrointestinal function and disease. In Robinson, H.J. and Vane, J.R. (eds.) Prostaglandin Synthetase Inhibitors, pp. 363–372. (New York: Raven Press)Google Scholar
  3. 3.
    Robert, A., Nezamins, J.E. and Phillips, J.P. (1968). Effects of prostaglandin E1 on gastric secretion and ulcer formation in the rat. Gastroenterology, 55, 481–487PubMedGoogle Scholar
  4. 4.
    Bennett, A., Eley, K.G. and Scholes, G.B. (1968). Effects of prostaglandins E1 and E2 on human, guinea pig and rat isolated small intestine. Br. J. Pharmacol., 34, 630–638PubMedGoogle Scholar
  5. 5.
    Collier, H.O.J. (1974). Prostaglandin synthetase inhibitors and the gut. In Robinson, H.J. and Vane, J.R. (eds.) Prostaglandin Synthetase Inhibitors, pp. 121–133. (New York: Raven Press)Google Scholar
  6. 6.
    Bennett, A. (1971). Cholera and prostaglandins. Nature (London), 232, 536CrossRefGoogle Scholar
  7. 7.
    Bennett, A. (1976). Prostaglandins and the alimentary tract. In Karim, S.M.M. (ed.). Prostaglandins: Physiological Pharmacological and Pathological Aspects, pp. 247–276. (Baltimore: University Park)Google Scholar
  8. 8.
    Whittle, B.J.R. (1976). Gastric antisecretory and antiulcer activity of prostaglandin E2 methyl analogs. In Samuelsson, B. and Paoletti, R (eds.). Advances in Prostaglandin and Thromboxane Research. Vol. II, p. 948. (New York: Raven Press)Google Scholar
  9. 9.
    Robert A. (1977). Prostaglandins and the digestive system. In Ramwell, P.W. (ed.). The Prostaglandins, pp. 225–266. (New York: Plenum)Google Scholar
  10. 10.
    Dreyling, K.W., Hoppe, U., Kleine, A., Kozuschek, W. and Peskar, B.M. (1987) Leukotriene formation in the gastrointestinal tract and effects of anti-inflammatory drugs. In Rainsford, K.D. and Velo, G.P. (eds.). Side Effects of Anti-inflammatory Drugs, pp. 101–112. (Lancaster, MTP Press)Google Scholar
  11. 11.
    Rainsford, K.D. (1979). Prostaglandins and the development of gastric mucosal damage by anti-inflammatory drugs. In Rainsford, K.D. and Ford-Hutchinson, A.W. (eds.). Prostaglandins and Inflammation, Agents Actions, Suppl. 6, pp. 193–210. (Basel: Birkaeuser)Google Scholar
  12. 12.
    Miller, T.A. (1983). Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am. J. Physiol., 245, G601–G623PubMedGoogle Scholar
  13. 13.
    Whittle, B.J.R. and Boughton-Smith, N.K. (1984). Biosynthesis of exogenous arachidonate products involved in gastric damage and protection. In Paton, W., Mitchell, J. and Turner, P. (eds.) Proceedings of the 9th International Pharmacology Congress, IUPHAR, London, Vol. 3, pp. 345–354. (London: Macmillan)Google Scholar
  14. 14.
    Hawkey, C.J. and Rampton, D.S. (1985). Prostaglandins and the gastro-intestinal mucosa: are they important in its function, disease or treatment? Gastroenterology, 89, 1162–1168PubMedGoogle Scholar
  15. 15.
    Jobke, A., Peskar, B.A. and Peskar, B.M. (1973). On the specificity of prostaglandins A2 and E2. FEBS Lett., 37, 192–196PubMedCrossRefGoogle Scholar
  16. 16.
    Peskar, B. M. (1978). Radioimmunoassay fur Prostaglandine. Z. Gastroenterologie, 16, 1–8Google Scholar
  17. 17.
    Peskar, B.M. Seybert, H.W. and Peskar, B.A. (1980). Synthesis and metabolism of endogenous prostaglandins by human gastric mucosa. In Samuelsson, B., Ramwell, P.W. and Paoletti, R. Advances in Prostaglandin and Thromboxane Research, Vol. 8, pp. 1511–1551. (New York: Raven Press)Google Scholar
  18. 18.
    Lee, D.K.H., Cohen, R., Gilliar, J., Muller, B. and Smith, T. (1986). A subchronic study of the effect of etodolac on the gastric mucosal prostaglandin levels in the rat. Agents Actions, 19, 228–232PubMedGoogle Scholar
  19. 19.
    Hoppe, U., Hoppe, E.M., Peskar, B.M. and Peskar, B.A. (1986). Radioimmunoassay for leukotriene E4. Use of determination of total sulfidopeptide—leukotriene release from rat gastric mucosa. FEBS Lett., 208, 26–30PubMedCrossRefGoogle Scholar
  20. 20.
    Pace-Asciak, C.R. and Rangaraj, G. (1977). Distribution of prostaglandin biosynthetic pathways in several rat tissues. Formation of 6-ketoprostaglandin F. Biochim. Biophys. Acta, 486, 579–582PubMedGoogle Scholar
  21. 21.
    Rainsford, K.D., Fox, S.A. and Osborne, D.J. (1984). Comparative effects of some nonsteroidal anti-inflammatory drugs on the ultrastructural integrity and prostaglandin levels in the rat gastric mucosa: Relationship to drug uptake. Scand. J. Gastroenterol., 19 (Suppl. 101), 35–68Google Scholar
  22. 22.
    Goswanni, S., Mai, J., Bruckner, G. and Kinsella, J. E. (1981). Extraction and purification of prostaglandins and thromboxane from biological samples for gas-chromatographic analysis. Prostaglandins, 22, 693–702CrossRefGoogle Scholar
  23. 23.
    Moncada, S., Salmon, J.A., Vane, J.R. and Whittle, B.J.R. (1977). Formation of prostacyclin and its product 6-oxo-PGF by the gastric mucosa of several species. J. Physiol., 275, 4P–5PGoogle Scholar
  24. 24.
    Konturek, S.J., Piastucki, I., Brozozowski, T., Radecki, T., Dembinska-Kiec, A., Zmuda, A. and Gryglewski, R. (1981). Role of prostaglandins in the formation of aspirin-induced gastric ulcers. Gastroenterology, 80, 4–9PubMedGoogle Scholar
  25. 25.
    Green, K., Aly, A. and Johansson, C. (1981). Measurements of prostaglandin biosynthesis in the gastrointestinal tract: biochemical and technical problems. Prostaglandins, 21, (Suppl. 1), 1–7PubMedCrossRefGoogle Scholar
  26. 26.
    Peskar, B.M., Holland, A. and Peskar, B.A. (1974). Quantitative determination of prostaglandins in human gastric juice by radioimmunoassay. Clin. Chim. Acta, 55, 21–27PubMedCrossRefGoogle Scholar
  27. 27.
    Minuz, P., Cavallin, G., Brocco, G., Degan, M., Jeunet, F., Kunorits, G., Riela, A. and Velo, G.P. (1986). Effect of carprofen and indomethacin on gastric function and the content of prostaglandins E2 and F in the human gastric juice. Hepato-gastroenterology, 33, 20–22PubMedGoogle Scholar
  28. 28.
    Whittle, B.J.R. (1983). The potentiation of taurocholate-induced rat gastric erosions following parenteral administration of cyclo-oxygenase inhibitors. Br. J. Pharmacol., 80, 545–551PubMedGoogle Scholar
  29. 29.
    Pace-Asciak, C.R. and Carrara, M.C. (1978). Stability of authentic PGI2 during routine extraction. Clarification of the nature and sequences of products formed by the rat stomach including the origin of ozonolysis products reported in 1971. Prostaglandins, 16, 397–410PubMedCrossRefGoogle Scholar
  30. 30.
    Rainsford, K.D. and Willis, C. (1982). Relationship of gastric mucosal damage induced in pigs by anti-inflammatory drugs to their effects on prostaglandin production. Dig. Dis. Sci., 27, 624–635PubMedCrossRefGoogle Scholar
  31. 31.
    Rainsford, K.D., Fox, S.A. and Osborne, D.J. (1985). Relationship between any absorption, inhibition of cyclooxygenase and lipoxygenase pathways and the development of gastric mucosal damage by non-steroidal anti-inflammatory drugs in rats and pigs. In Bailey, M. J. (ed.) Advances in Prostaglandins, Leukotrienes and Lipoxins, pp. 639–653. (New York: Plenum Press)Google Scholar
  32. 32.
    Rainsford, K.D. (1987). Mechanisms of gastric contrasted with intestinal damage by nonsteroidal anti-inflammatory drugs. In Rainsford, K.D. and Velo, G.P. (eds.) Side Effects of Anti-inflammatory Drugs, pp. 3–26. (Lancaster: MTP Press)Google Scholar
  33. 33.
    Rainsford, K.D. (1987). Mechanisms of gastrointestinal damage by non-steroidal antiinflammatory drugs. In Szabo, S. and Pfeiffer, C.J. (eds.) Experimental Gastric Ulcer. (Boca Raton: CRC Press) (In press)Google Scholar
  34. 34.
    Robert, A. (1984). Mechanisms of cytoprotection. In Paton, W., Mitchell, J. and Turner, P. (eds.) Proceedings of the 9th International Congress of Pharmacology, IUPHAR, Vol. 3 pp. 355–359. (London: Macmillan)Google Scholar
  35. 35.
    Miller, T.A. (1983). Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am. J. Physiol., 245, G601–G623PubMedGoogle Scholar
  36. 36.
    Jacobson, E.D. (1986). Direct and adaptive cytoprotection. Dig. Dis. Sci., 31 (Suppl.), 28S–31SPubMedCrossRefGoogle Scholar
  37. 37.
    Needleman, P. (1978). Experimental criteria for evaluating prostaglandin biosynthesis and intrinsic function. Biochem. Pharmacol., 17, 1515–1518CrossRefGoogle Scholar
  38. 38.
    Baker, R., Jaffe, B.M., Read, J.D., Shaw, B. and Venables, C.W. (1978). Endogenous prostaglandins and gastric secretion in the cat. J. Physiol., 278, 451–460PubMedGoogle Scholar
  39. 39.
    Flemstrom, G., Briden, S. and Kivilaakso, E. (1984). Stimulation by BW 755 C and inhibition by cysteamine of duodenal epithelial alkaline secretion suggest a role of endogenous prostaglandin in mucosal protection. Scand. J. Gastroenterol., 19 (Suppl. 92), 101–105Google Scholar
  40. 40.
    Gaut, Z.N., Baruth, H., Randall, L.O., Ashley, C. and Paulsrud, J.R. (1975). Steroisomeric relationships among anti-inflammatory activity, inhibition of platelet aggregation, and inhibition of prostaglandin synthetase. Prostaglandins, 10, 1–8Google Scholar
  41. 41.
    Shen, T.Y. (1985). Indomethacin, sulindac and their analogs. In Rainsford, K.D. (ed.) Antiinflammatory and Anti-rheumatic Drugs, Vol. 1, pp. 149–159. (Boca Raton, CRC Press)Google Scholar
  42. 42.
    Greenberg, B.P. and Bernstein, J. (1985). Fenbufen. In Rainsford, K.D. (ed), Anti-inflammatory and Anti-rheumatic Drugs, Vol. II. pp. 87–103. (Boca Raton: CRC Press)Google Scholar
  43. 43.
    Shen, T.Y. and Winter, C.A. (1977). Chemical and biological studies on indomethacin, sulindac and their analogs. Adv. Drug Res., 12, 89–245Google Scholar
  44. 44.
    Rainsford, K.D. (1981). Comparison of the gastric ulcerogenic activity of new non-steroidal anti-inflammatory drugs in stressed rats. Br. J. Pharmacol., 73, 79c–80cGoogle Scholar
  45. 45.
    Rainsford, K.D. and Whitehouse, M. W. (1976). Gastric irritancy of aspirin and its congeners: Anti-inflammatory activity without this side effect. J. Pharm. Pharmacol., 28, 599–601PubMedCrossRefGoogle Scholar
  46. 46.
    Whitehouse, M.W., Rainsford, K.D., Young, T.G. Ardlie, N.G. and Brune, K. (1977). Alternatives to aspirin derived from biological sources. Agents Actions, Suppl. 1, 43–47Google Scholar
  47. 47.
    Whitehouse, M.W. and Rainsford, K.D. (1980). Esterification of acidic anti-inflammatory drugs suppresses their gastrotoxicity without adversely affecting their anti-inflammatory activity in rats. J. Pharm. Pharmacol., 32, 795–796PubMedCrossRefGoogle Scholar
  48. 48.
    Rainsford, K.D., Schweitzer, A., Green, P., Whitehouse, M.W. and Brune, K. (1980). Biodistribution in rats of some salicylates with low gastric ulcerogenicity. Agents Actions, 20, 452–464Google Scholar
  49. 49.
    Rainsford, K.D., Schweitzer, A. and Brune, K. (1981). Autoradiographic and biochemical observations on the distribution of non-steroidal anti-inflammatory drugs. Arch. Int. Pharmacodyn., 250, 180–194PubMedGoogle Scholar
  50. 50.
    Whittle, B.J.R. (1981) Temporal relationship between cyclo-oxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology, 80, 94–98PubMedGoogle Scholar
  51. 51.
    Rainsford, K.D. (1975). Electronmicroscopic observations on the effects of orally administered aspirin and aspirin—bicarbonate mixtures on the development of gastric mucosal damage in the rat. Gut, 16, 514–527PubMedCrossRefGoogle Scholar
  52. 52.
    Ligumsky, M., Golanska, E.M., Hansen, D.G. and Kaufrman, G.L. (1985). Aspirin can inhibit mucosal cyclo-oxygenase without causing lesions in the rat. Gastroenterology, 84, 756–761Google Scholar
  53. 53.
    Reinhardt, M.C. and deWeck, A.L. (1984). Immunological actions of aspirin in relation to hypersensitivity reactions. In Rainsford, K.D. and Velo, G.P. (eds.) Side-effects of Antiinflammatory/Analgesic Drugs, pp. 209–217. (New York: Raven Press)Google Scholar
  54. 54.
    Rainsford, K.D. (1984). Aspirin and the Salicylates, pp. 238–239. (London: Butterworths)Google Scholar
  55. 55.
    Rainsford, K.D. (1987). Effects of modulation of the 5-lipoxygenase pathway on the development of gastric mucosal lesions induced by nonsteroidal anti-inflammatory drugs in cholinomimetic treated mice. Agents Actions, 21, 316–319PubMedCrossRefGoogle Scholar
  56. 56.
    Rainsford, K.D. (1984). The mechanisms of gastro-intestinal ulceration by non-steroidal anti-inflammatory drugs. In Rainsford, K.D. and Velo, G.P. (eds.) Side Effects of Antiinflammatory/Analgesic Drugs, pp. 51–64. (New York: Raven Press)Google Scholar
  57. 57.
    Van Kolfschoten, A.A., Hagelin, F. and van Noordwijk, J. (1984). Butyl hydroxy toluene antagonizes the gastric toxicity but not the pharmacological activity of acetylsalicylic acid in rats. Naunyn-Schmeidebergs Arch. Pharmacol., 325, 283–285CrossRefGoogle Scholar
  58. 58.
    Swingle, K.F., Bell, R.L. and Moore, G.G.I. (1985). Anti-inflammatory activity of antioxidants. In Rainsford, K.D. (ed.) Anti-inflammatory and Anti-rheumatic Drugs, Vol. 3, pp. 105–126. (Boca Raton, CRC Press)Google Scholar
  59. 59.
    Hurley, J.W. and Crandall, L.A. (1963). The effects of salicylates upon the dog’s stomach: A gastroscopic photographic evaluation. In Dixon, A. St. J., Martin, B.K., Smith, M.J. H. and Wood, P.H.N. (eds.) Salicylates, an International Symposium. pp. 213–216. (London: Churchill)Google Scholar
  60. 60.
    Graham, D.Y., Lacey Smith, J. and Dobbs, S.M. (1983). Gastric adaptation occurs with aspirin administration in man. Dig. Dis. Sci., 28, 1–6PubMedCrossRefGoogle Scholar
  61. 61.
    Halter, F., Baumgartner, A., Varga, L. and Koelz, H.R. (1987). Both E-prostaglandins and prolonged indomethacin treatment exert trophic effects on the gastric mucosa. In Rainsford, K.D. and Velo, G.P. (eds.) Side Effects of Anti-inflammatory Drugs. pp. 133–142. (Lancaster, MTP Press)Google Scholar
  62. 62.
    Krupp, P., Menasse, R., Riesterer, L. and Ziel, R. (1976). The biological significance of inhibition of prostaglandin synthesis. In Lewis, G.P. (ed.) The Role of Prostaglandins in Inflammation, pp. 106–115. (Berne: Hans Huber)Google Scholar
  63. 63.
    Boughton-Smith, N.K. and Whittle, B.J.R. (1983). Stimulation and inhibition of prostacyclin formation in the gastric mucosa and ileum in vitro by anti-inflammatory agents. Br. J. Pharmacol., 78, 173–180PubMedGoogle Scholar
  64. 64.
    Collins, P.O., Tavares, I.A. and Bennett, A. (1987). Inhibition of prostanoid synthesis by anti-inflammatory drugs in human gastric mucosa. In Rainsford, K.D. and Velo, G.P. (eds.) Side Effects of Anti-inflammatory Drugs, Vol. II, pp. 97–100. (Lancaster, MTP Press)Google Scholar
  65. 65.
    Brune, K., Rainsford, K.D., Wagner, K. and Peskar, B.A. (1981). Inhibition by antiinflammatory drugs of prostaglandin production in cultured macrophages. Factors influencing the apparent drug effects. Naunyn-Schmeidebergs Arch. Pharmacol., 315, 269–276CrossRefGoogle Scholar
  66. 66.
    Danon, A., Leibsen, V. and Assoldine, G. (1983). Effects of aspirin, indomethacin, flufenamic acid and paracetamol on prostaglandin output from rat stomach and renal papilla in vitro and ex vivo. J. Pharm. Pharmacol., 35, 576–579PubMedCrossRefGoogle Scholar
  67. 67.
    Fitzpatrick, F.A. and Wynalda, M.A. (1976). In vivo suppression of prostaglandin biosynthesis by non-steroidal anti-inflammatory agents. Prostaglandins, 12, 1037–1051PubMedCrossRefGoogle Scholar
  68. 68.
    Le Duc, L.E. and Needleman, P. (1979). Regional localization of prostacyclin and thromboxane synthesis in dog stomach and intestinal tract. J. Pharmacol. Exp. Ther., 211, 181–188Google Scholar
  69. 69.
    Skoglund, M.L., Gerber, J.G., Murphy, R.C. and Nies, A.S. (1980). Prostaglandin production by intact isolated gastric parietal cells. Eur. J. Pharmacol., 66, 145–148PubMedCrossRefGoogle Scholar

Copyright information

© MTP Press Limited 1988

Authors and Affiliations

  • K. D. Rainsford

There are no affiliations available

Personalised recommendations